Feliza Mirasol is the science editor for 

Articles

Johnson & Johnson gains NM26, a Phase II-ready bispecific antibody in development for atopic dermatitis, boosting its immune-mediated and inflammatory disease portfolio.

Johnson & Johnson Gains Bispecific Antibody with Completion of Numab Subsidiary Acquisition

The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

PRAC is recommending that patients who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) consider the risk of delayed gastric emptying before undergoing surgery with general anesthesia or deep sedation.

EMA’s PRAC Offers Recommendations for Glucagon-like Peptide-1 Receptor Agonists and Glatiramer Acetate

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

Pfizer and Evotec Partner for Drug Discovery

The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services. 

uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards.

Roche to Reintroduce nAMD Treatment in US After FDA Approves Updates

Other indications for which the Sanofi treatment has been approved include atopic dermatitis, asthma, and chronic rhinosinusitis.

EU Makes First-in-World Approval of Dupixent as Targeted Therapy for Uncontrolled COPD

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

GSK and CureVac Enter into Licensing Agreement

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

News